{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=38", "query": { "condition": "Metastatic Solid Tumor Cancers", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 1754, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T02:45:51.623Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04458259", "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "PF-07265807", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2020-09-24", "completion_date": "2024-11-15", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 25, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458259" }, { "nct_id": "NCT05907980", "title": "A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ROSE12", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chugai Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 209, "start_date": "2023-05-24", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 5, "location_summary": "Philadelphia, Pennsylvania • Providence, Rhode Island • Nashville, Tennessee + 2 more", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05907980" }, { "nct_id": "NCT04381650", "title": "A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "TAK-981", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-08-17", "completion_date": "2024-10-29", "has_results": true, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Orange, California • Stanford, California + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04381650" }, { "nct_id": "NCT06578624", "title": "Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "SA53-OS (phase 1)", "type": "DRUG" }, { "name": "SA53-OS (phase 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lamassu Bio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-03-10", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 3, "location_summary": "Canton, Ohio • Cleveland, Ohio", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06578624" }, { "nct_id": "NCT02265510", "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCB052793", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "pomalidomide", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" }, { "name": "INCB039110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2014-09-10", "completion_date": "2019-02-27", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 14, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02265510" }, { "nct_id": "NCT01971515", "title": "First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "MSC2363318A", "type": "DRUG" }, { "name": "MSC2363318A plus Trastuzumab", "type": "DRUG" }, { "name": "MSC2363318A plus Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2013-12-13", "completion_date": "2018-08-09", "has_results": false, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01971515" }, { "nct_id": "NCT01425008", "title": "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Metastatic Melanoma", "Solid Tumor", "Neoplasm" ], "interventions": [ { "name": "MLN2480", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2011-09-15", "completion_date": "2018-10-16", "has_results": true, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 9, "location_summary": "San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425008" }, { "nct_id": "NCT07086768", "title": "Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "BSI-082", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lei Zheng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2026-01-26", "completion_date": "2028-08-07", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07086768" }, { "nct_id": "NCT04222413", "title": "Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Pancreatic Cancer", "Pediatric Solid Tumor", "Advanced Breast Cancer", "Malignant Peripheral Nerve Sheath Tumor", "Colorectal Neoplasms" ], "interventions": [ { "name": "Metarrestin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 116, "start_date": "2020-10-27", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 2, "location_summary": "Fairway, Kansas • Bethesda, Maryland", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04222413" }, { "nct_id": "NCT03489343", "title": "Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "Sym023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-05-24", "completion_date": "2020-06-03", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-10-17T02:45:51.623Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03489343" } ] }